Digital health technologies in clinical trials are no longer “nice to have”; they are becoming a core operating capability for participant-centered execution, decentralized elements, and faster, higher-quality data flow. This article explains which technologies matter most, how regulators frame expectations, and how to govern interoperability, data integrity, and AI responsibly.
Digital health technologies in clinical trials are no longer “nice to have”; they are becoming a core operating capability for participant-centered execution, decentralized elements, and faster, higher-quality data flow. This article explains which technologies matter most, how regulators frame expectations, and how to govern interoperability, data integrity, and AI responsibly.
Digital health technologies in clinical trials are no longer “nice to have”; they are becoming a core operating capability for participant-centered execution, decentralized elements, and faster, higher-quality data flow. This article explains which technologies matter most, how regulators frame expectations, and how to govern interoperability, data integrity, and AI responsibly.
Digital health technologies in clinical trials are no longer “nice to have”; they are becoming a core operating capability for participant-centered execution, decentralized elements, and faster, higher-quality data flow. This article explains which technologies matter most, how regulators frame expectations, and how to govern interoperability, data integrity, and AI responsibly.
Digital health technologies in clinical trials are no longer “nice to have”; they are becoming a core operating capability for participant-centered execution, decentralized elements, and faster, higher-quality data flow. This article explains which technologies matter most, how regulators frame expectations, and how to govern interoperability, data integrity, and AI responsibly.
Advancing Patient Access, Affordability, and High-Touch Support ACCESS USA 2026 arrives at a pivotal moment for U.S. market access and patient support. New affordability dynamics, evolving reimbursement and policy requirements,
In today’s complex pharmaceutical landscape, patient support programs have become integral to successful product commercialization. These programs serve as a bridge between pharma companies, healthcare providers, and patients – helping
My mom taught me all the most important things I know. Things like the importance of family, how to show up for the ones we love, and, of course, the
Designing support programs for patients in rare conditions is a complex endeavor. The traditional approaches that work in high‑volume disease areas often fail when applied to orphan settings. Low patient
In today’s fast-paced pharmaceutical market, commercial leaders are under pressure to deliver more personalized patient support while demonstrating clear value. Patient services are evolving from a back-end support role to